koers vandaag 4% gezakt, maar was laatste tijd wel erg hard gestegen.
MorphoSys Reports Preliminary, Unaudited Financial Results for 2010 and Provides First Outlook on 2011.January 21, 2011 / 12:22 am, CET
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) today reported preliminary, unaudited financial results for the full-year 2010 according to International Financial Reporting Standards (IFRS). For 2010, MorphoSys expects full year revenues of approximately EUR 87 million (2009: EUR 81.0 million) and an operating profit of approximately EUR 10 million (2009: EUR 11.4 million). The deviation from guidance issued by the Company on December 10, 2010 (revenues of EUR 91-94 million and operating profit of EUR 13-16 million) is related to the final accounting treatment of the recently signed Pfizer deal. This accounting treatment has no impact on the overall economics of the agreement with Pfizer, or on any cash flows arising from the deal.
For 2011, MorphoSys projects full year revenues of at least EUR 105 million and an operating profit of at least EUR 10 million.
"2010 was a stellar year for MorphoSys," commented Dave Lemus, Chief Financial Officer of MorphoSys. "Our growth story is very strong and we expect to see revenue growth in excess of 20% in 2011."